Adjuvant surgical therapy for patients with initially‐unresectable pancreatic cancer with long‐term favorable responses to chemotherapy
- 1 April 2011
- journal article
- research article
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 18 (5), 712-716
- https://doi.org/10.1007/s00534-011-0391-8
Abstract
Background To evaluate the prognostic impact of surgical intervention for initially‐unresectable pancreatic ductal adenocarcinomas with long‐term favorable responses to chemotherapy. Method Twelve patients with initially‐unresectable pancreatic ductal carcinomas who underwent radical surgery after a favorable response to chemotherapy for six months or longer in principle were enrolled in this study. We retrospectively reviewed the charts of these 12 patients and performed a survival analysis. Results Initially, the included patients were unable to undergo resection secondary to locally‐advanced disease in eight patients and metastatic disease in four patients. The length of preoperative therapy was five to 44 months (median 12). The operative procedure included resection of the area initially involved by tumor and regional major vessels. The postoperative mortality and morbidity rates were 0% for patients with locally‐advanced disease and 50% in those with metastatic disease. R0 resection was achieved in nine patients (75%) and pathological CR was seen in one patient. Estimated overall five‐year survival from initial therapy was 50.0%. The survival rate (0% at 5 years) of the four patients with metastatic disease as the cause of initial unresectability was significantly worse than that (100% at 5 years) of the eight patients with locally‐advanced disease (p = 0.0014). Conclusion Surgical intervention should be considered for patients with initially‐unresectable pancreatic cancers who demonstrate long‐term favorable responses to chemotherapy. R0 resection may significantly contribute to cure, especially in patients with initially locally‐advanced disease. Large cohort prospective studies will be necessary to demonstrate the efficacy of this strategy.Keywords
This publication has 15 references indexed in Scilit:
- Analysis of 5‐Year Survivors After a Macroscopic Curative Pancreatectomy for Invasive Ductal AdenocarcinomaWorld Journal of Surgery, 2010
- Management and prognosis of pancreatic cancer over a 30-year periodBritish Journal of Cancer, 2009
- Chemoradiotherapy in the Management of Locally Advanced Pancreatic Carcinoma: A Qualitative Systematic ReviewJournal of Clinical Oncology, 2009
- Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysisJournal of Hematology & Oncology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal Of Cancer, 2009
- Long-Term Survival (5-20 Years) After Pancreatectomy for Pancreatic Ductal AdenocarcinomaPancreas, 2008
- Prognostic Factors in Japanese Patients with Advanced Pancreatic Cancer Treated with Single-agent Gemcitabine as First-line TherapyJapanese Journal of Clinical Oncology, 2008
- Distal Pancreatectomy With En Bloc Celiac Axis Resection for Locally Advanced Pancreatic Body CancerAnnals of Surgery, 2007
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Journal of Clinical Oncology, 1997
- Preoperative Chemoradiation and Pancreaticoduodenectomy for Adenocarcinoma of the PancreasArchives of Surgery, 1992